FDA grants approval to Axsome Therapeutics’ migraine medication containing Betadex Sulfobutylether Sodium
The U.S. Food and Drug Administration has approved Axsome Therapeutics’ new migraine treatment tablet on 30 January 2025 [1]. Marketed
Tag: Symbravo